| $350M | ||
| $172M | ||
| $115M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $121,432 | 6 | 100 |
Sells | $0 | 0 | 0 |
| Germano Geno J | director | 2 | $55,800 | 0 | $0 | $55,800 |
| Ellis Sean | director | 2 | $34,620 | 0 | $0 | $34,620 |
| Toledano Miranda Jayne | Chief Executive Officer | 1 | $19,912 | 0 | $0 | $19,912 |
| Taitel Haya | director | 1 | $11,100 | 0 | $0 | $11,100 |
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Over the last 12 months, insiders at Entera Bio Ltd. have bought $121,432 and sold $0 worth of Entera Bio Ltd. stock.
On average, over the past 5 years, insiders at Entera Bio Ltd. have bought $99,823 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Germano Geno J (director) — $55,800. Ellis Sean (director) — $34,620. Toledano Miranda Jayne (Chief Executive Officer) — $19,912.
The last purchase of 20,000 shares for transaction amount of $26,000 was made by Germano Geno J (director) on 2026‑03‑09.
| 2026-03-09 | Germano Geno J | director | 20,000 0.0454% | $1.30 | $26,000 | +0.75% | ||
| 2026-03-05 | Ellis Sean | director | 10,000 0.0218% | $1.23 | $12,300 | +8.94% | ||
| 2026-02-10 | Taitel Haya | director | 7,500 0.0162% | $1.48 | $11,100 | -5.52% | ||
| 2026-02-10 | Germano Geno J | director | 20,000 0.0436% | $1.49 | $29,800 | -5.52% | ||
| 2026-02-09 | Ellis Sean | director | 18,000 0.0366% | $1.24 | $22,320 | +3.38% | ||
| 2025-12-29 | Toledano Miranda Jayne | Chief Executive Officer | 11,000 0.0252% | $1.81 | $19,912 | -19.44% | ||
| 2024-01-12 | Taitel Haya | director | 9,500 0.0311% | $0.99 | $9,405 | +66.06% | ||
| 2024-01-10 | Taitel Haya | director | 7,615 0.0264% | $0.77 | $5,864 | +126.22% | ||
| 2023-12-22 | LIEBERMAN GERALD M | director | 23,952 0.0901% | $0.71 | $17,006 | +174.62% | ||
| 2023-12-22 | Toledano Miranda Jayne | Chief Executive Officer | 23,952 0.0901% | $0.71 | $17,006 | +174.62% | ||
| 2023-08-22 | Taitel Haya | director | 18,000 0.0572% | $0.62 | $11,216 | +55.88% | ||
| 2023-08-21 | LIEBERMAN GERALD M | director | 20,000 0.0715% | $0.59 | $11,784 | +74.38% | ||
| 2023-08-21 | Ellis Sean | director | 40,000 0.1456% | $0.60 | $24,000 | +74.38% | ||
| 2023-04-04 | Toledano Miranda Jayne | Chief Executive Officer | 30,000 0.1073% | $1.01 | $30,300 | -18.78% | ||
| 2022-11-14 | LIEBERMAN GERALD M | director | 38,000 0.1348% | $0.57 | $21,740 | +44.46% | ||
| 2022-11-14 | Yaacov-Garbeli Dana | Chief Financial Officer | 26,580 0.0883% | $0.54 | $14,247 | +44.46% | ||
| 2022-11-11 | Ellis Sean | director | 30,000 0.1104% | $0.53 | $15,900 | +61.90% | ||
| 2022-11-11 | Toledano Miranda Jayne | Chief Executive Officer | 50,000 0.1846% | $0.53 | $26,585 | +61.90% | ||
| 2022-11-11 | Yaacov-Garbeli Dana | Chief Financial Officer | 30,000 0.1083% | $0.52 | $15,600 | +61.90% | ||
| 2022-07-21 | LIEBERMAN GERALD M | 19,491 0.0602% | $1.68 | $32,803 | -52.59% |
| Toledano Miranda Jayne | Chief Executive Officer | 426575 0.8654% | $1.21M | 4 | 0 | +72.58% |
| Ellis Sean | director | 188098 0.3816% | $534,198.32 | 5 | 0 | +27.9% |
| Germano Geno J | director | 40000 0.0812% | $113,600.00 | 2 | 0 | |
| Taitel Haya | director | 0 0% | $0 | 4 | 0 | +82.72% |
| LIEBERMAN GERALD M | director | 226961 0.4605% | $644,569.24 | 4 | 0 | +60.22% |
| Yaacov-Garbeli Dana | Chief Financial Officer | 56580 0.1148% | $160,687.20 | 2 | 0 | +53.18% |
$9,405,928 | 107 | 12.61% | $150.45M | |
$15,998,851 | 75 | 1.70% | $157.58M | |
$66,137,559 | 49 | 6.29% | $135.62M | |
$19,086,607 | 44 | 0.14% | $155.01M | |
$64,733,831 | 40 | 5.69% | $129.8M | |
$161,692,548 | 20 | 18.00% | $138.88M | |
$762,249 | 19 | 3.16% | $155.56M | |
$33,128,160 | 18 | -13.64% | $125.8M | |
Entera Bio Ltd. (ENTX) | $277,862 | 15 | 59.79% | $139.98M |
$13,486,672 | 11 | 82.26% | $123.42M | |
$9,999,920 | 10 | -40.03% | $137.46M | |
$344,394 | 8 | -22.26% | $125.96M | |
$20,729,984 | 5 | 51.71% | $163.16M | |
$36,049,976 | 5 | -3.82% | $142.07M | |
$15,551,156 | 3 | 98.82% | $141.72M | |
$193,101 | 3 | -25.20% | $146.39M | |
$8,997,728 | 2 | -11.16% | $147.8M | |
$2,857,000 | 2 | -5.23% | $136.09M | |
$2,590,000 | 1 | 37.38% | $125.54M |
| Increased Positions | 11 | +47.83% | 313,763 | +3.41% |
| Decreased Positions | 8 | -34.78% | 176,135 | -1.92% |
| New Positions | 4 | New | 176,677 | New |
| Sold Out Positions | 4 | Sold Out | 151,684 | Sold Out |
| Total Postitions | 26 | +13.04% | 9M | +1.5% |
| Knoll Capital Management, Llc | $10,411.00 | 12.79% | 5.88M | 0 | 0% | 2025-09-30 |
| Point72 Asset Management, L.P. | $2,086.00 | 2.56% | 1.18M | -2M | -56.31% | 2025-09-30 |
| Marshall Wace, Llp | $1,110.00 | 1.36% | 627,330 | +627,330 | New | 2025-09-30 |
| Schonfeld Strategic Advisors Llc | $1,004.00 | 1.23% | 566,956 | -37,566 | -6.21% | 2025-09-30 |
| Parkman Healthcare Partners Llc | $497.00 | 0.61% | 280,822 | -75,000 | -21.08% | 2025-09-30 |
| Northern Trust Corp | $263.00 | 0.32% | 148,668 | -52,077 | -25.94% | 2025-09-30 |
| Bessemer Group Inc | $249.00 | 0.31% | 140,843 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $156.00 | 0.19% | 88,400 | +24,100 | +37.48% | 2025-09-30 |
| Susquehanna International Group, Llp | $119.00 | 0.15% | 67,177 | +18,300 | +37.44% | 2025-09-30 |
| Signature Estate & Investment Advisors Llc | $84.00 | 0.1% | 47,328 | 0 | 0% | 2025-09-30 |